Cibinetide

Cibinetide
Clinical data
Other namesARA-290; ARA290; PHBSP; pHBSP peptide; pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; Pyroglutamate helix B surface peptide; UEQLERALNSS
Drug classErythropoietin receptor agonist
Identifiers
  • (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC51H84N16O21
Molar mass1257.324 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
  • InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
  • Key:WZTIQQBMSJTRBR-WYKNNRPVSA-N

Cibinetide (INNTooltip International Nonproprietary Name; USANTooltip United States Adopted Name; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions. It was under development for the treatment of depressive disorders, but development for this indication was discontinued. The drug is under development by Araim Pharmaceuticals. Modified derivatives with a longer duration of action have also been developed.

See also

References

  1. 1 2 3 4 "Cibinetide - Araim Pharmaceuticals". AdisInsight. 28 June 2022. Retrieved 23 October 2024.
  2. 1 2 3 "Delving into the Latest Updates on Cibinetide with Synapse". Synapse. 8 October 2024. Retrieved 23 October 2024.
  3. ↑ Peng B, Kong G, Yang C, Ming Y (February 2020). "Erythropoietin and its derivatives: from tissue protection to immune regulation". Cell Death Dis. 11 (2) 79. doi:10.1038/s41419-020-2276-8. PMC 6997384. PMID 32015330.
  4. ↑ Winicki NM, Nanavati AP, Morrell CH, Moen JM, Axsom JE, Krawczyk M, et al. (2023). "A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan". Frontiers in Cardiovascular Medicine. 9 1096887. doi:10.3389/fcvm.2022.1096887. PMC 9889362. PMID 36741836.
  5. ↑ Liu G, Liang J, Li W, Jiang S, Song M, Xu S, et al. (2024). "The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury". International Immunopharmacology. 138 112452. doi:10.1016/j.intimp.2024.112452.